CERTARA INC

Rona Anhalt’s steady RSU‑to‑cash trades show Certara’s HR chief is invested in long‑term value, boosting investor confidence in the company’s biosimulation‑driven growth.

Insider buying at Certara signals confidence amid a steep decline; analysts weigh the biotech’s predictive‑model platform, reimbursement shifts, and risky metrics for a cautious investment outlook.

Certara insider buy: modest 14,510 shares, signals confidence amid steep price drop, regulatory delays, and cloud‑shift opportunity.